Sotatercept
Term · Oncology and biomedicine · MLC-T-ONC-016828
A soluble fusion protein composed of the extracellular domain of the activin receptor type IIA (ActRIIA) linked to the Fc portion of human IgG1 with anabolic bone activity. Sotatercept selectively binds to activin, inhibiting its binding to ActRIIA and ActRIIA signaling, resulting in the stimulation of osteoblast activity and the inhibition of osteoclast activity and so normal bone formation and increased bone mineral density and strength. The Fc moiety of this fusion protein binds to the salvage receptor FcRN, preventing its lysosomal degradation and so extending its half-life in the circulatory system.
| Identifier | MLC-T-ONC-016828 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | soluble activin receptor Type IIa IgG-Fc fusion protein ACE-011; decoy activin receptor ACE-011 |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-016828",
"term": "Sotatercept",
"field": "Oncology and biomedicine",
"definition": "A soluble fusion protein composed of the extracellular domain of the activin receptor type IIA (ActRIIA) linked to the Fc portion of human IgG1 with anabolic bone activity. Sotatercept selectively binds to activin, inhibiting its binding to ActRIIA and ActRIIA signaling, resulting in the stimulation of osteoblast activity and the inhibition of osteoclast activity and so normal bone formation and increased bone mineral density and strength. The Fc moiety of this fusion protein binds to the salvage receptor FcRN, preventing its lysosomal degradation and so extending its half-life in the circulatory system.",
"synonyms": [
"soluble activin receptor Type IIa IgG-Fc fusion protein ACE-011",
"decoy activin receptor ACE-011"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/sotatercept/"
}
Record 15,196 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.